
CAS 1672691-74-5
:4-(4-Morfolinil)-1,2,5-tiadiazol-3-il N-ciclooctil-N-metilcarbamato
- 4-(4-Morpholinyl)-1,2,5-thiadiazol-3-yl N-cyclooctyl-N-methylcarbamate
- JZP-430
- Carbamic acid, N-cyclooctyl-N-methyl-, 4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl ester
JZP-430
CAS:JZP-430 is an effective, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) (IC50: 44 nM).Fórmula:C16H26N4O3SPureza:99.78%Cor e Forma:SolidPeso molecular:354.47Ref: TM-T15635
1mg48,00€5mg74,00€10mg109,00€25mg190,00€50mg274,00€100mg393,00€200mg520,00€1mL*10mM (DMSO)82,00€4-(4-Morpholinyl)-1,2,5-thiadiazol-3-ylN-cyclooctyl-N-methylcarbamate
CAS:Fórmula:C16H26N4O3SPureza:99%Peso molecular:354.4676Ref: IN-DA01ENKY
1mg61,00€5mg118,00€10mg174,00€25mg247,00€50mg555,00€100mgA consultar250mgA consultarJZP 430
CAS:JZP 430 is a pharmaceutical compound, which is synthesized in a laboratory setting with advanced techniques of medicinal chemistry. It functions as a modulator of specific neural pathways associated with sleep regulation. By targeting and interacting with specific neurotransmitter systems, JZP 430 aims to optimize the sleep-wake cycle, offering potential therapeutic benefits for sleep disorders. Its mode of action involves binding to neural receptors, enhancing sleep quality, and reducing the latency to sleep onset. The applications of JZP 430 are focused on treating conditions such as narcolepsy and idiopathic hypersomnia, where irregular sleep patterns significantly impact daily functioning. The compound is undergoing rigorous clinical evaluations to determine its efficacy and safety profile, aiming to fill the current therapeutic gaps in managing complex sleep disorders.
Fórmula:C16H26N4O3SPureza:Min. 95%Peso molecular:354.5 g/molRef: 3D-XRC69174
Produto descontinuado



